Skip to the main content.
Other Therapy Areas

Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.

Learn More →

1 min read

SCOPE Summit for Clinical Operations Executives 2015

Veristat-SCOPEVeristat is pleased to announce that we will exhibit at the SCOPE Summit for Clinical Operations Executives conference in Orlando, FL at the Hyatt Regency Orlando on February 24-26. We would be delighted to meet with you to discuss your clinical program needs at this unique industry event. If you are not registered, please register  here.

Come listen to your peers address critical questions around issues related to each aspect of clinical trial planning and management, including:
  • Data Integration
  • Feasibility
  • Site Selection and Management
  • Patient Engagement
  • Recruitment and Retention
  • Mobile Technology
  • Project Management
  • Forecasting
  • Quality (QbD) in Trial Conduct
  • Risk-Based Monitoring
  • Post-Marketing Studies
  • Pharmacovigilance

Who is Veristat?

Veristat is a distinct full-service CRO with a 20-year history of bringing critical thinking, in-depth experience, and scientific expertise to advance our clients' clinical programs.

Schedule a time to speak with Veristat, by contacting: 

JoAnn Eckhoff at  joann.eckhoff@veristat.com
or call JoAnn directly at 617-901-0408.
Learn more about us at  www.veristat.com.
Veristat's President Speaks at 3rd Annual Chief Medical Officer Summit

Veristat's President Speaks at 3rd Annual Chief Medical Officer Summit

Veristat's President, John Balser, PhD, discusses the key factors in building successful clinical trials at the 3rd Annual Chief Medical Officer...

Read More
Veristat Strengthens Statistical Consulting and Adaptive Design Trial Expertise

Veristat Strengthens Statistical Consulting and Adaptive Design Trial Expertise

Veristat Strengthens Statistical Consulting and Adaptive Design Trial Expertise

Read More
Shaping the Future of Myeloma, Together

Shaping the Future of Myeloma, Together

Shaping the Future of Myeloma, Together

Read More